Plain-English translation of NCT02693535 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The TAPUR Study tests whether cancer medications already approved by the FDA work well when prescribed specifically for patients whose tumors have certain genetic changes. Researchers will use genetic testing to match patients with medications designed to target their tumor's specific genetic abnormality. This study involves several different medications, each paired with particular genetic changes, to see which combinations are safe and effective.
Many cancer patients stop responding to standard treatments, and doctors need better ways to match patients with medications that will actually work for their specific tumor. This medication is designed to target genetic changes in cancer cells, but we need real-world evidence that prescribing it based on genetic testing actually helps patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, your doctor will prescribe the medication matched to your tumor's genetic change, and you'll take it according to the standard dosing schedule. You'll have regular appointments with your cancer team to monitor how well the medication is working and check for side effects. Your progress will be tracked in the study registry, and researchers will collect information about your response to treatment to help answer whether genetic matching improves outcomes for future patients.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States